Provided by Tiger Trade Technology Pte. Ltd.

Biogen

196.26
-4.9200-2.45%
Volume:616.25K
Turnover:121.21M
Market Cap:28.79B
PE:22.33
High:201.00
Open:200.00
Low:192.50
Close:201.18
52wk High:202.41
52wk Low:110.04
Shares:146.70M
Float Shares:146.23M
Volume Ratio:0.85
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):8.79
EPS(LYR):8.79
ROE:7.39%
ROA:6.14%
PB:1.58
PE(LYR):22.33

Loading ...

Biogen Posts Q4 Beat, Analysts Raise Price Targets On 'Significant Pipeline Diversification'

Benzinga_recent_news
·
48 mins ago

Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings

Benzinga
·
Yesterday

Biogen : Wedbush Raises Target Price to $187 From $178

THOMSON REUTERS
·
Yesterday

Biogen : Truist Securities Raises Target Price to $193 From $190

THOMSON REUTERS
·
Yesterday

Piper Sandler Adjusts Price Target on Biogen to $177 From $157, Maintains Neutral Rating

MT Newswires Live
·
Yesterday

Biogen, Inc : H.c. Wainwright Raises Target Price to $228 From $194

THOMSON REUTERS
·
Yesterday

Biogen Is Maintained at Neutral by Piper Sandler

Dow Jones
·
Yesterday

BUZZ-Street View: Spotlight turns to Biogen's pipeline

Reuters
·
Yesterday

U.S. RESEARCH ROUNDUP-Align Technology, Biogen, Citigroup

Reuters
·
Yesterday

China prüft Biogens Antrag auf subkutane LEQEMBI-Formulierung im beschleunigten Verfahren

Reuters
·
Yesterday

BRIEF-Biogen Says Biologics License Application For Subcutaneous Formulation Of Leqembi For Treatment Of Early Alzheimer’S Disease Designated For Priority Review In China

Reuters
·
Yesterday

Biogen: Biologics License Application for Subcutaneous Formulation of Leqembi for Treatment of Early Alzheimer’s Disease Designated for Priority Review in China

THOMSON REUTERS
·
Yesterday

Biogen: Undervalued Cash Flows and Growing Leqembi Franchise Support Raised Price Target and Buy Rating

TIPRANKS
·
Yesterday

Biogen price target raised to $200 from $190 at Wells Fargo

TIPRANKS
·
Yesterday

Biogen price target raised to $190 from $156 at Morgan Stanley

TIPRANKS
·
Yesterday

Biogen price target raised to $215 from $185 at Citi

TIPRANKS
·
Yesterday

Biogen: Solid Near-Term Execution but High-Risk Pipeline Keeps Rating at Hold

TIPRANKS
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Centene (CNC) and Biogen (BIIB)

TIPRANKS
·
Yesterday

Biogen: Limited Near-Term Growth and Execution Risks Justify Neutral Hold Rating

TIPRANKS
·
Yesterday

Biogen Trial Updates Test Investor Views On Pipeline Strength And Valuation

Simply Wall St.
·
Feb 07